Medtronic completed the acquisition of Intersect ENT for $1.1bn.

Medtronic, a medical technology company, completed the acquisition of Intersect ENT, a medical technology company, for $1.1bn. "This acquisition directly aligns with our commitment to delivering continuous innovation that helps ENT patients. Intersect ENT's sinus implants are clinically proven to offer relief and healing to patients suffering from chronic rhinosinusitis. Combining this innovative technology with our established global presence and sales infrastructure will allow us to broaden our capabilities while expanding access to these valuable therapies," Vince Racano, Intersect ENT President.